asa statement on glp 1 Glucagon-Like Peptide Receptor Agonists and Aspiration Risk Aspiration risk tops anesthesiologists' concerns
Description
Researchers found that about 44% of users reported at least one side effect, with gastrointestinal symptoms remaining the most common
Novel pricing/reimbursement models like outcomes-based agreements could improve access
So, protecting your muscle mass while taking GLP-1s is much more than just preventing so-called Ozempic butt, especially postpartum
The glucagon-like peptides: a double-edged therapeutic sword
The specific combination of glycine with semaglutide has not been tested in large randomized controlled trials
Safety information
